This company has been acquired
このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Prometheus Biosciences バランスシートの健全性
財務の健全性 基準チェック /66
Prometheus Biosciences has a total shareholder equity of $697.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $758.4M and $60.8M respectively.
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$713.67m |
| エクイティ | US$697.62m |
| 負債合計 | US$60.80m |
| 総資産 | US$758.41m |
財務の健全性に関する最新情報
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth
May 17
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Recent updates
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth
May 17Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M
Aug 11We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases
Dec 08Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Prometheus Biosciences: Precision Medicine For IBD
Sep 22財務状況分析
短期負債: RXDX's short term assets ($726.4M) exceed its short term liabilities ($19.3M).
長期負債: RXDX's short term assets ($726.4M) exceed its long term liabilities ($41.5M).
デット・ツー・エクイティの歴史と分析
負債レベル: RXDX is debt free.
負債の削減: RXDX had no debt 5 years ago.
貸借対照表
キャッシュ・ランウェイ分析
過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。
安定したキャッシュランウェイ: RXDX has sufficient cash runway for more than 3 years based on its current free cash flow.
キャッシュランウェイの予測: RXDX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 48.2% each year